Table 3.
Mean HbA1c by age-group and CGM usage at baseline and 12 and 24 months after CGM start
| CGM usage | Age-group (years) | Baseline | 12 months | 24 months |
|---|---|---|---|---|
| HbA1c (%) | HbA1c (%) | HbA1c (%) | ||
| <25% | 0–10 | 7.8 (1.1) | 7.5 (1.2) | 7.7 (1.3) |
| 10–15 | 8.2 (1.4) | 8.1 (1.6) | 8.5 (1.8) | |
| 15–21 | 8.5 (1.6) | 9.0 (2.0)* | 8.8 (1.8)* | |
| >75% | 0–10 | 7.8 (1.1) | 7.5 (1.0)* | 7.4 (0.9)* |
| 10–15 | 8.2 (1.4) | 7.9 (1.3) | 7.9 (1.3) | |
| 15–21 | 8.5 (1.6) | 7.8 (1.3)* | 8.0 (1.6)* |
Data are mean (SD). P values for comparison between the baseline and 12 months post-CGM start and baseline and 24 months post-CGM start were calculated using the GEE model with a Gaussian family distribution and an exchangeable correlation matrix with identity link function.
*
Denotes having a P value of <0.05.